Gastrointestinal Stromal Tumors: A Broad Clinical Spectrum from Incidental Discovery to Acute Gastrointestinal Bleeding;Gastrointestinale Stromatumoren (GIST): Variable Klinische Manifestationen vom Zufallsbefund bis zur Akuten Gastrointestinalen Blutung

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 3, 2004, Pages 233-242

  Siewert, E ^a   Tietze, L ^a   Maintz, C ^b   Geier, A ^a   Dietrich, C G ^a   Matern, S ^a   Gartung, Carsten ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Hamatologisch Onkologische Praxis   (Germany)

Author keywords

Gastrointestinal bleeding; Gastrointestinal mesenchymal tumor (GIMT); Gastrointestinal stromal tumor (GIST); Leiomyoma; Schwannoma; STI 571 imatinib

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; ESOPHAGUS SURGERY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HEMORRHAGIC SHOCK; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; LEIOMYOMA; NEURILEMOMA; PROGNOSIS; RECURRENT DISEASE;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARDIA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GASTRECTOMY; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HUMANS; INCIDENTAL FINDINGS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, CONNECTIVE TISSUE; PIPERAZINES; POLYPS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SHOCK, HEMORRHAGIC; STOMACH NEOPLASMS; STROMAL CELLS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 1642314215     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-812729     Document Type: Article

References (39)

1. Mazur MT, Clark HB. Gastric stromal tumor: Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519
2. Miettinen M, Lasota J. Gastointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12
3. Fletcher CDM, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465
4. Eyden B, Chorneyko KA, Shanks JH et al. Contribution of electron microscopy to understanding cellular differentiation in mesenchymal tumors of the gastrointestinal tract: a study of 82 tumors. Ultrastruct Pathol 2002; 26: 269-285
5. Lee JR, Joshi V, Griffin Jr JW et al. Gastrointestinal autonomic nerve tumor - immunohistochemical and meolecular identity with gastrointestinal stromal tumor. Am J Surg Pathol 2001; 25: 979-987
6. Hirota S. Gastrointestinal stromal tumors: their origin and cause. Int J Clin Oncol 2001; 6: 1-5
7. Sarlomo-Rikala M, Miettinen M. Gastric schwannoma - a clinicopathological analysis of six cases. Histopathology 1995; 27: 355-360
8. Kwon MS, Lee SS, Ahn GH. Schwannomas of the gastrointestinal tract: clinicopathological features of 12 cases including a case of esophageal tumor compared with those of gastrointestinal stromal tumors and leiomyomas of the gastrointestinal tract. Pathol Res Pract 2002; 198: 605-613
9. Reichardt P, Pink D, Hohenberger P. Paradigmenwechsel in der Therapie gastrointestinaler Strumatumoren. Onkologe 2002; 8: 378-383
10. Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
11. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. The Lancet 2001; 358: 1421-1423
12. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2002; 38, Suppl. 5: S83-S87
13. DeMatteo RP, Heinrich MC, El-Rifai WM et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-477
14. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
15. Joensuu H, Robert PJ, Sarloma-Rikala M et al. Effect of the tysrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056
16. Soft Tissue Sarcomas. In: DeVita VT, Hellman S, Rosenberg SA (Hrsg). Cancer, principles and practice of oncology. Philadelphia: Lippincott, 1993
17. Chou FF, Eng HL, Sheen-Chen SM. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery 1996; 119: 117
18. Pidhorecky MD, Cheney RT, Kraybill WG et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000; 7: 705-712
19. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000, 15: 1293-1301
20. Sarlomo-Rikala M, Tsujimura T, Lendahl U et al. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS 2002; 110: 499-507
21. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13: 1134-1142
22. Hornick JL, Fletcher CDM. Immunohistochemical staining for KIT (CD117) in soft tissue sacomas is very limited in distribution. Am J Clin Pathol 2002; 117: 188-193
23. Miettinen M, Salomo-Rikala M, Sobin LH et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24: 211-222
24. Miettinen M, Salomo-Rikala M, Sobin LH. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors - a clinicopathologic and immunohistochemical study of eighty-eight cases. Mod Pathol 2001; 14: 950-956
25. Plaat BE, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-3220
26. Miettinen M, El-Rifai W, Sobin et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors. Hum Pathol 2002; 33: 478-483
27. Mechtersheimer G, Lehnert T, Penzel R et al. Gastrointestinale Stromatumoren - eine morphologisch und molekular eigenständige Tumorentität mit neuer therapeutischer Perspektive. Pathologe 2003; 24: 182-191
28. Heinrich MC, Rubin BP, Longley BJ et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-495
29. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38, Suppl. 5: S39-S51
30. Paner GP, Silberman S, Hartman G et al. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res 2003; 23: 2253-2260
31. Heinrich MC, Corless CL, Blanke CD et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2002; 21: 2a (abstract)
32. Joensuu H, Fletcher C, Dimitrijevic S et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-664
33. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Euro J Cancer 2002; 38 (Suppl. 5): S37-S38
34. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors - recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58
35. DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-KIT), and a molecular inhibitor (STI571). Ann Surg Oncol 2002; 9: 831-839
36. Brümming P, Andersson J, Meis-Kindblom JM et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-464
37. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003; 17: 829-838
38. Paterson SC, Smith KD, Holyoake TL et al. Is there a cloud in the silver lining for imatinib? Br J Cancer 2003; 88: 983-987
39. Thambi P, Sausville EA. STI571 (imatinib mesylate): the tale of a targeted therapy. Anti-Cancer Drugs 2002; 13: 111-114